The Effectiveness of Breathing Therapy in Patients With Schizophrenia

NCT07150507 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2025-09-02

No results posted yet for this study

Summary

This study aimed to determine the effects of breathing therapies on sleep disturbances and fatigue in patients with schizophrenia.The study will be conducted at a CMHC in Ağrı province between May and August 2021. At the CMHC, community-based mental health services are provided to patients with severe mental disorders (schizophrenia, bipolar disorder) who are in remission as assessed by a psychiatrist. The study is planned to be conducted with patients who meet the study criteria, without using a sample selection method. Patients over the age of 18 registered with CMHC and followed with a diagnosis of schizophrenia were contacted by phone and invited to CMHC. The study was conducted with patients who met the inclusion criteria and agreed to participate. Data will be collected using the Descriptive Characteristics Form, the DSM-5 Sleep Disorder Scale, and the Brief Fatigue Inventory. The experimental group received eight sessions of respiratory therapy.The control group received no intervention. The study sample size was calculated using the GPower computer program. A power analysis performed at α=0.05 revealed an effect size of 150.153 (d=0.8), providing 90% power. Therefore, it was calculated that a minimum of 68 patients should be included in the sample.

Conditions

  • Breathing Therapy

Interventions

OTHER

Session 1: Preparation Session

\*Meeting Patients \*Introducing the Content of Psychoeducation \*Emphasizing the Importance of Regular and Timely Attendance at Training \*Determining Training Dates \*Sharing Individuals' Experiences and Expectations

OTHER

Session 2: Recognizing the Illness

\*What is Schizophrenia? \*What are its Symptoms? \*What Does Treatment Include?

OTHER

Session 3: Treatment Evaluation

\*Things to Consider When Using Medication \*Side Effects of Medication \*Exacerbation of Schizophrenia \*Precursor Symptoms.

OTHER

Session 4: What is anger?

\*What are the symptoms of anger? \*What are the methods for coping with anger?

OTHER

Session 5: Communication

\*What is communication? \*The importance of communication. \*Fundamentals of communication, working on "I" language. \*Ways to prevent communication difficulties.

OTHER

Session 6: What is relaxation?

What is progressive relaxation? Introducing a relaxation CD

OTHER

Session 7: Relaxation

Practicing the relaxation CD with patients

OTHER

Session 8: Evaluation

\*Reinforcing what has been learned. \*Evaluating the program. \*Obtaining feedback

Sponsors & Collaborators

  • Ataturk University

    lead OTHER

Principal Investigators

  • Mine Cengiz lecturer doctor · Ataturk University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-29
Primary Completion
2022-11-15
Completion
2023-05-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07150507 on ClinicalTrials.gov